MediciNova's MN-166 Abstract Accepted for NEALS 2024 Meeting
![MediciNova's MN-166 Abstract Accepted for NEALS 2024 Meeting](https://investorshangout.com/images/blog/ihnews-MediciNova%27s%20MN-166%20Abstract%20Accepted%20for%20NEALS%202024%20Meeting.jpg)
MediciNova's Significant Milestone with MN-166
MediciNova, Inc., based in La Jolla, California, recently announced a major achievement that has set the stage for further developments in neurodegenerative disease treatment. The company revealed that an abstract concerning its clinical trial of MN-166, also known as ibudilast, has been accepted for presentation at the upcoming Annual NEALS Meeting. This meeting will bring together experts in the field of amyotrophic lateral sclerosis (ALS), providing a platform for MediciNova to showcase its innovative research.
About the COMBAT-ALS Clinical Trial
The COMBAT-ALS Phase 2b/3 trial of MN-166 is a critical study aimed at evaluating the efficacy and safety of this drug in patients with ALS. The presentation of the trial's details is scheduled for October 23, 2024, in a poster format, to be presented by Dr. Björn Oskarsson, a key figure in this research and an Associate Professor of Neurology. This opportunity underscores the commitment of MediciNova to advance treatment options for patients with ALS.
Presentation Details
The accepted abstract will cover essential aspects of the trial. Key details include:
- Submission ID: 164
- Title: COMBAT-ALS Phase 2b/3 Trial of MN-166 (Ibudilast) in ALS: Study Design and Trial Update
- Session: Poster Presentation
- Date: October 23, 2024
Understanding MN-166 (Ibudilast)
MN-166 is a small molecule compound renowned for its action as a phosphodiesterase type-4 (PDE4) inhibitor, coupled with its ability to modulate inflammatory cytokines. This drug is in late-stage clinical development not only for ALS but also for other conditions such as progressive multiple sclerosis, degenerative cervical myelopathy, glioblastoma, and even long COVID. Its multifaceted action makes it a promising candidate in the realm of neurodegenerative therapies.
About MediciNova, Inc.
MediciNova is devoted to developing innovative therapies targeting inflammatory, fibrotic, and neurodegenerative conditions. The company boasts a diverse pipeline of clinical programs, spearheaded by its lead compound, MN-166. This drug is pushing forward in Phase 3 trials targeting both ALS and degenerative cervical myelopathy. Additionally, MN-001 (tipelukast) is part of their pipeline, currently expanding its development for metabolic-associated fatty liver disease.
With a strong foundation in clinical research, MediciNova is well-positioned to advance multiple initiatives with the potential for impactful results. Their commitment to prioritizing patient care and innovative science continues to drive the company's success.
Frequently Asked Questions
What is the significance of the NEALS meeting?
The NEALS meeting is a renowned platform for the latest research in ALS and related fields, allowing experts to share findings and advancements.
What is MN-166 used for?
MN-166 is primarily investigated for its effects in neurodegenerative diseases, including ALS, progressive multiple sclerosis, and other related conditions.
Who is presenting the MN-166 abstract?
Dr. Björn Oskarsson, a notable Associate Professor of Neurology, will present the abstract regarding the MN-166 clinical trial.
What stage is MN-166 currently in for ALS treatment?
MN-166 is currently in Phase 3 clinical trials for ALS, indicating significant progress in its development.
Where can I learn more about MediciNova?
Further information about MediciNova, including their initiatives and contact details, can be found on their official website or by reaching out via email.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Caprolactam Market Growth Forecasts: Key Insights for 2034
- Innovent Biologics Gains FDA Fast Track Designation for IBI363
- Pomerantz Investigates Investor Claims for Chemours (CC)
- Investigating Concerns for DraftKings Inc. Investors - DKNG
- W. P. Carey Inc. Under Investigation For Securities Fraud Claims
- Yen and Dollar Steady as Markets Brace for Job Data Insights
- PTX Metals Inc. Moves Forward with Share Consolidation Plan
- Kraton Corporation Announces Global Price Increase for Products
- Prologis, Inc. Declares Quarterly Dividend for Investors
- VELMENI® Achieves FDA Clearance for Cutting-Edge Dental AI
- Telix Pharmaceuticals' TLX101 Shows Promise for Glioblastoma
- Oldcastle BuildingEnvelope Enhances StormMax® Products for Protection
- Medical Billing Outsourcing Market Set for Explosive Growth
- Cipher Mining Reports Robust August 2024 Operational Results
- Investigation Launched for WEBTOON Entertainment Investors
- Ibotta Inc. Under Investigation for Alleged Securities Fraud
- BofA Downgrades China's Growth Forecast Amid Economic Concerns
- Credit Rating Agencies Agree to Settle for $49 Million in Penalties
- 36Kr Holdings Inc. Earnings Report: Strategies for Growth Ahead
- Swiss Life’s H1 2024 Financial Results Show Strong Performance
- Industrial Chain Drives Market Set for USD 831 Million Growth
- Dimethylolpropionic Acid Market Forecast: Growth Driven by Eco-Friendly Solutions
- Psychedelic Drugs Market Forecast: Growth Driven by Mental Health
- Brookfield Reveals New Dividend Rate for Series 40 Shares
- Levulinic Acid Market Forecast: Growth to $208.52 Million
Recent Articles
- Pomerantz Law Firm Investigates Cardlytics, Inc. (NASDAQ: CDLX)
- AI Video Generator Market Expected to Hit USD 2980 Million
- Investigation Launched into WisdomTree, Inc. - WT Investors
- Investigation into Piedmont Lithium Inc. by Pomerantz Law Firm
- Warner Bros. and Trailer Park Group Launch Beetlejuice App
- Royalty Pharma Secures $150 Million for Ascendis's Yorvipath
- Rob Conti Elevated to CIO of First Watch Restaurant Group
- Invesco Advisers, Inc. Updates Investment Restrictions for Funds
- Sportsman’s Warehouse Reports Q2 2024 Financial Performance
- ParaZero Reports Strong Progress and Financial Performance
- ACM Research Unveils Innovative Ultra C bev-p Etching Tool
- Citi Appoints Achintya Mangla as New Head of Investment Banking
- Toll Brothers Unveils Luxe Condominiums in Chantilly, Virginia
- Teamsters Secure Historic Agreement for Airline Workers' Rights
- Investors Urged to Participate in MongoDB Securities Case
- Exploring the Rise of the Aluminum Alloy Wheel Market
- American Institutes for Research Takes Charge of OPTN Upgrade
- Later Strengthens Leadership with Key Executive Appointments
- Spartan Capital Securities Celebrates 2024 Summer Interns
- Graphic Processing Unit Market Forecast: USD 1.41 Trillion by 2034
- Vicor Corporation Addresses Recent Litigation Claims
- Equature's 2024.3 Software Revolutionizes Public Safety Operations
- Costco to Expand with Four New Locations by End of 2024
- HomeSafe Alliance Achieves Milestone Of 100 Military Moves
- Xiaohongshu's Street Life Festival Draws Record Attendance and Engagement